Aparajita Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aparajita Pal has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Dipa Talukdar
Department of Biophysics, Bose Institute, Kolkata, India
3 shared publicationsManju Ray
3 shared publicationsAdrita Chakrabarti
2 shared publicationsAnirban Roy
Department of Biophysics, Bose Institute, P 1/12, CIT Road, Scheme VIIM, Kolkata, 700 054, West Bengal, India
2 shared publicationsChitra Mandal
Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Biology, Kolkata, India
2 shared publications- Manju Ray
Dept. of Biophysics, Bose Institute, P 1/12, CIT Scheme VII M, Kolkata, 700 054, WB, India; Dept. of Chemistry, Institute of Applied Science & Humanities GLA University Mathura, 17km Stone, NH-2, Mathura-Delhi Road, Mathura, 281 406, UP, India
2 shared publications
Latest Publications
- 17 December 2024
- Published by Elsevier in Microbial Pathogenesis
- Vol. 199, 107234
Enlightening the promising role of nanoparticle-based treatments against Naegleria fowleri-induced primary amoebic meningoencephalitis: A brain-eating disease
- 17 December 2024
- Published by Elsevier in Microbial Pathogenesis
- Vol. 199, 107234
Enlightening the promising role of nanoparticle-based treatments against Naegleria fowleri-induced primary amoebic meningoencephalitis: A brain-eating disease
- 29 November 2023
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 976, 173011
Stretchable and lightweight 2D MXene-based elastomeric composite foam for suppressing electromagnetic interference
- 29 November 2023
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 976, 173011
Stretchable and lightweight 2D MXene-based elastomeric composite foam for suppressing electromagnetic interference
- 16 July 2023
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 21 (3) , 1-8
Current Prospects of Phytochemical-Based Treatment for Ovarian Cancer: A Brief Review
- 16 July 2023
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 21 (3) , 1-8
Current Prospects of Phytochemical-Based Treatment for Ovarian Cancer: A Brief Review
- Open Access
- 1 January 2023
- Published by International Academic Publishing House
- p. 01-13
Deciphering the pharmacotherapeutic aspects of an ethnomedicinal plant Bacopa monnieri (Brahmi)
Indian Ayurveda is the birthplace of traditional classical medicines from ancient ages as it has vast reservoir of medicinal plants. Amongst all medicinal plants, Bacopa monnieri or Brahmi is an ethno-medicinal herb abundantly found in tropical and sub-tropical regions of India. This herb is composed of enormous bioactive phytochemicals like bacosides, alkaloids, glycosides, sterols and flavonoids. Bacosides are the most significant among all and bear enormous neuromedicinal properties and protect brain from neuronal damage and modulate the imbalance of neurotransmitter signalling. Extracts of Brahmi can prevent brain aging, enhance memory learning and perception ability. Notably, it’s reactive oxygen species (ROS) quenching, antioxidant properties, anticancer, anti-inflammatory, anti-epileptic, anti-depressant, anti-stress, gastrointestinal, endocrinological, cardioprotective, hepatoprotective features are experimentally proven in animal model. Administration of Brahmi extract can restore the cognition and other neuronal disorders in Alzheimer’s and Parkinson’s patients. To avoid few adverse effects of Bacopa, combination with synthetic drugs or formation of its nanoparticulate form may be recommended. The immense important pharmacological role of Bacopa will beconcised in this chapter.
- 1 January 2023
- Published by International Academic Publishing House
- p. 01-13
Open AccessDeciphering the pharmacotherapeutic aspects of an ethnomedicinal plant Bacopa monnieri (Brahmi)
Indian Ayurveda is the birthplace of traditional classical medicines from ancient ages as it has vast reservoir of medicinal plants. Amongst all medicinal plants, Bacopa monnieri or Brahmi is an ethno-medicinal herb abundantly found in tropical and sub-tropical regions of India. This herb is composed of enormous bioactive phytochemicals like bacosides, alkaloids, glycosides, sterols and flavonoids. Bacosides are the most significant among all and bear enormous neuromedicinal properties and protect brain from neuronal damage and modulate the imbalance of neurotransmitter signalling. Extracts of Brahmi can prevent brain aging, enhance memory learning and perception ability. Notably, it’s reactive oxygen species (ROS) quenching, antioxidant properties, anticancer, anti-inflammatory, anti-epileptic, anti-depressant, anti-stress, gastrointestinal, endocrinological, cardioprotective, hepatoprotective features are experimentally proven in animal model. Administration of Brahmi extract can restore the cognition and other neuronal disorders in Alzheimer’s and Parkinson’s patients. To avoid few adverse effects of Bacopa, combination with synthetic drugs or formation of its nanoparticulate form may be recommended. The immense important pharmacological role of Bacopa will beconcised in this chapter.
- 30 April 2016
- Published by Springer Nature in Amino Acids
- Vol. 48 (8) , 2003-2013
Creatine supplementation with methylglyoxal: a potent therapy for cancer in experimental models
The anti-cancer effect of methylglyoxal (MG) is now well established in the literature. The main aim of this study was to investigate the effect of creatine as a supplement in combination with MG both in vitro and in vivo. In case of the in vitro studies, two different cell lines, namely MCF-7 (human breast cancer cell line) and C2C12 (mouse myoblast cell line) were chosen. MG in combination with creatine showed enhanced apoptosis as well as higher cytotoxicity in the breast cancer MCF-7 cell line, compared to MG alone. Pre-treatment of well-differentiated C2C12 myotubes with cancerogenic 3-methylcholanthrene (3MC) induced a dedifferentiation of these myotubes towards cancerous cells (that mimic the effect of 3MC observed in solid fibro-sarcoma animal models) and subsequent exposure of these induced cancer cells with MG proved to be cytotoxic. Thus, creatine plus ascorbic acid enhanced the anti-cancer effects of MG. In contrast, when normal C2C12 muscle cells or myotubes (mouse normal myoblast cell line) were treated with MG or MG plus creatine and ascorbic acid, no detrimental effects were seen. This indicated that cytotoxic effects of MG are specifically limited towards cancer cells and are further enhanced when MG is used in combination with creatine and ascorbic acid. For the in vivo studies, tumors were induced by injecting Sarcoma-180 cells (2 × 106 cells/mouse) in the left hind leg. After 7 days of tumor inoculation, treatments were started with MG (20 mg/kg body wt/day, via the intravenous route), with or without creatine (150 mg/kg body wt/day, fed orally) and ascorbic acid (50 mg/kg body wt/day, fed orally) and continued for 10 consecutive days. Significant regression of tumor size was observed when Sarcoma-180 tumor-bearing mice were treated with MG and even more so with the aforesaid combination. The creatine-supplemented group demonstrated better overall survival in comparison with tumor-bearing mice without creatine. In conclusion, it may be stated that the anti-cancer effect of MG is enhanced by concomitant creatine supplementation, both in chemically transformed (by 3MC) muscle cells in vitro as well as in sarcoma animal model in vivo. These data strongly suggest that creatine supplementation may gain importance as a safe and effective supplement in therapeutic intervention with the anti-cancer agent MG.
- 30 April 2016
- Published by Springer Nature in Amino Acids
- Vol. 48 (8) , 2003-2013
Creatine supplementation with methylglyoxal: a potent therapy for cancer in experimental models
The anti-cancer effect of methylglyoxal (MG) is now well established in the literature. The main aim of this study was to investigate the effect of creatine as a supplement in combination with MG both in vitro and in vivo. In case of the in vitro studies, two different cell lines, namely MCF-7 (human breast cancer cell line) and C2C12 (mouse myoblast cell line) were chosen. MG in combination with creatine showed enhanced apoptosis as well as higher cytotoxicity in the breast cancer MCF-7 cell line, compared to MG alone. Pre-treatment of well-differentiated C2C12 myotubes with cancerogenic 3-methylcholanthrene (3MC) induced a dedifferentiation of these myotubes towards cancerous cells (that mimic the effect of 3MC observed in solid fibro-sarcoma animal models) and subsequent exposure of these induced cancer cells with MG proved to be cytotoxic. Thus, creatine plus ascorbic acid enhanced the anti-cancer effects of MG. In contrast, when normal C2C12 muscle cells or myotubes (mouse normal myoblast cell line) were treated with MG or MG plus creatine and ascorbic acid, no detrimental effects were seen. This indicated that cytotoxic effects of MG are specifically limited towards cancer cells and are further enhanced when MG is used in combination with creatine and ascorbic acid. For the in vivo studies, tumors were induced by injecting Sarcoma-180 cells (2 × 106 cells/mouse) in the left hind leg. After 7 days of tumor inoculation, treatments were started with MG (20 mg/kg body wt/day, via the intravenous route), with or without creatine (150 mg/kg body wt/day, fed orally) and ascorbic acid (50 mg/kg body wt/day, fed orally) and continued for 10 consecutive days. Significant regression of tumor size was observed when Sarcoma-180 tumor-bearing mice were treated with MG and even more so with the aforesaid combination. The creatine-supplemented group demonstrated better overall survival in comparison with tumor-bearing mice without creatine. In conclusion, it may be stated that the anti-cancer effect of MG is enhanced by concomitant creatine supplementation, both in chemically transformed (by 3MC) muscle cells in vitro as well as in sarcoma animal model in vivo. These data strongly suggest that creatine supplementation may gain importance as a safe and effective supplement in therapeutic intervention with the anti-cancer agent MG.
- Open Access
- 1 May 2015
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10 (1) , 3499-3518
Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect
Purpose: The normal metabolite methylglyoxal (MG) specifically kills cancer cells by inhibiting glycolysis and mitochondrial respiration without much adverse effect upon normal cells. Though the anticancer property of MG is well documented, its gradual enzymatic degradation in vivo has prompted interest in developing a nanoparticulate drug delivery system to protect it and also to enhance its efficacy. Materials and methods: MG-conjugated chitosan nanoparticles (Nano-MG) were prepared by conjugating the carbonyl group of MG with the amino group of chitosan polymer (Schiff’s base formation). Nano-MG were characterized in detail using the dynamic light scattering method, zeta potential measurement, Fourier transform infrared spectroscopy, and transmission electron microscopic analysis. Amount of MG anchored to Nano-MG, stability of Nano-MG, and in vitro release of MG from Nano-MG were estimated spectrophotometrically. Ehrlich ascites carcinoma (EAC) cells, human breast cancer cell line HBL-100, and lung epithelial adenocarcinoma cell line A549 were used as test systems to compare Nano-MG with bare MG in vitro. Cytotoxicity to EAC cells was evaluated by the trypan blue dye exclusion test, and cell viability of HBL-100 and A549 cells were studied using 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis of HBL-100 cells was assessed by flow cytometry and confocal microscopy. In vivo studies were performed on both EAC cells inoculated and also in sarcoma-180-induced solid tumor-bearing Swiss albino mice to assess the anticancer activity of Nano-MG in comparison to bare MG with varying doses, times, and administrative routes. Results: Fourier transform infrared spectroscopy revealed the presence of imine groups in Nano-MG due to conjugation of the amino group of chitosan and carbonyl group of MG with diameters of nanoparticles ranging from 50–100 nm. The zeta potential of Nano-MG was +21 mV and they contained approximately 100 µg of MG in 1 mL of solution. In vitro studies with Nano-MG showed higher cytotoxicity and enhanced rate of apoptosis in the HBL-100 cell line in comparison with bare MG, but no detrimental effect on normal mouse myoblast cell line C2C12 at the concerned doses. Studies with EAC cells also showed increased cell death of nearly 1.5 times. Nano-MG had similar cytotoxic effects on A549 cells. In vivo studies further demonstrated the efficacy of Nano-MG over bare MG and found them to be about 400 times more potent in EAC-bearing mice and nearly 80 times more effective in sarcoma-180-bearing mice. Administration of ascorbic acid and creatine during in vivo treatments augmented the anticancer effect of Nano-MG. Conclusion: The results clearly indicate that Nano-MG may constitute a promising tool in anticancer therapeutics in the near future.
- 1 May 2015
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10 (1) , 3499-3518
Open AccessNanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect
Purpose: The normal metabolite methylglyoxal (MG) specifically kills cancer cells by inhibiting glycolysis and mitochondrial respiration without much adverse effect upon normal cells. Though the anticancer property of MG is well documented, its gradual enzymatic degradation in vivo has prompted interest in developing a nanoparticulate drug delivery system to protect it and also to enhance its efficacy. Materials and methods: MG-conjugated chitosan nanoparticles (Nano-MG) were prepared by conjugating the carbonyl group of MG with the amino group of chitosan polymer (Schiff’s base formation). Nano-MG were characterized in detail using the dynamic light scattering method, zeta potential measurement, Fourier transform infrared spectroscopy, and transmission electron microscopic analysis. Amount of MG anchored to Nano-MG, stability of Nano-MG, and in vitro release of MG from Nano-MG were estimated spectrophotometrically. Ehrlich ascites carcinoma (EAC) cells, human breast cancer cell line HBL-100, and lung epithelial adenocarcinoma cell line A549 were used as test systems to compare Nano-MG with bare MG in vitro. Cytotoxicity to EAC cells was evaluated by the trypan blue dye exclusion test, and cell viability of HBL-100 and A549 cells were studied using 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis of HBL-100 cells was assessed by flow cytometry and confocal microscopy. In vivo studies were performed on both EAC cells inoculated and also in sarcoma-180-induced solid tumor-bearing Swiss albino mice to assess the anticancer activity of Nano-MG in comparison to bare MG with varying doses, times, and administrative routes. Results: Fourier transform infrared spectroscopy revealed the presence of imine groups in Nano-MG due to conjugation of the amino group of chitosan and carbonyl group of MG with diameters of nanoparticles ranging from 50–100 nm. The zeta potential of Nano-MG was +21 mV and they contained approximately 100 µg of MG in 1 mL of solution. In vitro studies with Nano-MG showed higher cytotoxicity and enhanced rate of apoptosis in the HBL-100 cell line in comparison with bare MG, but no detrimental effect on normal mouse myoblast cell line C2C12 at the concerned doses. Studies with EAC cells also showed increased cell death of nearly 1.5 times. Nano-MG had similar cytotoxic effects on A549 cells. In vivo studies further demonstrated the efficacy of Nano-MG over bare MG and found them to be about 400 times more potent in EAC-bearing mice and nearly 80 times more effective in sarcoma-180-bearing mice. Administration of ascorbic acid and creatine during in vivo treatments augmented the anticancer effect of Nano-MG. Conclusion: The results clearly indicate that Nano-MG may constitute a promising tool in anticancer therapeutics in the near future.
- 1 January 2014
- Published by Elsevier in Cellular Immunology
- Vol. 287 (1) , 27-35
Immunomodulation of macrophages by methylglyoxal conjugated with chitosan nanoparticles against Sarcoma-180 tumor in mice
- 1 January 2014
- Published by Elsevier in Cellular Immunology
- Vol. 287 (1) , 27-35
Immunomodulation of macrophages by methylglyoxal conjugated with chitosan nanoparticles against Sarcoma-180 tumor in mice
- 1 November 2008
- Published by Elsevier in International Immunopharmacology
- Vol. 8 (11) , 1503-1512
Activation of macrophages and lymphocytes by methylglyoxal against tumor cells in the host
- 1 November 2008
- Published by Elsevier in International Immunopharmacology
- Vol. 8 (11) , 1503-1512
Activation of macrophages and lymphocytes by methylglyoxal against tumor cells in the host